Since the first report of type 1 melatonin receptor (Mt1) and β-secretase 1 (Bace1) for the regulation of Aβ production, targeting Mt1 and Bace1 has been considered a powerful therapeutic approach for Alzheimer’s disease [167]. Here, BACE1 is linked to Alzheimer disease.